Tesamorelin: visceral fat, the liver and what the studies showed
Ukraine, Dnepr, st. 25 Sicheslavskaya Brigade (Rybinskaya St.), 119 ‑ 120
Ukraine, Dnepr, st. 25 Sicheslavskaya Brigade (Rybinskaya St.), 119 ‑ 120

Tesamorelin: visceral fat, the liver and what the studies showed

Tesamorelin (Egrifta): how it works, what studies showed for visceral fat with HIV and for liver fat, the numbers, the FDA label regimen and who should see a doctor first.

Tesamorelin: visceral fat, the liver and what the studies showed
Tesamorelin is an analogue of a hypothalamic hormone for visceral fat in HIV lipodystrophy. What the studies showed, what happens with the liver, blood sugar and IGF-1, how it is used and who should see a doctor first.

The main point

Tesamorelin (Egrifta) is a synthetic analogue of a hypothalamic hormone that "asks" the pituitary gland to release its own growth hormone. In the US it has been approved since 2010 for one task: to reduce excess abdominal fat in adults living with HIV and lipodystrophy (FDA label). The drug's strength is the precision of its target: it removes visceral fat, the fat that lies around the organs and is linked to metabolism. It is not a weight-loss drug: weight did not change in the trials (−0.4 and +0.2 kg, a non-significant difference), and subcutaneous fat did not decrease. Liver fat drew separate interest: in a study of 61 people its share fell by 4.1 percentage points vs placebo, that is 37% of baseline. Related topics: Resmetirom (Rezdiffra) for fatty liver disease and the HOMA-IR index.

Substance and formWhat it doesWhat the studies showedWho it is discussed for
Tesamorelin, subcutaneous injections, visceral fat in HIVboosts the body's own release of growth hormone806 people, 2 studies, 26 weeks: visceral fat −15.4% vs placeboadults with HIV and lipodystrophy (FDA indication)
Tesamorelin for fatty liver disease with HIVlowers the share of fat in the liver61 people, 1 study, 12 months: liver fat −4.1 percentage points (−37%)adults with HIV and liver fat (off-label)
Tesamorelin for abdominal obesity with reduced growth hormone, without HIVreduces visceral fat60 people, 1 study, 12 months: −35 cm² vs placeboadults without HIV, in a study
Tesamorelin in type 2 diabetessafety was studied53 people, 1 study, 12 weeks: diabetes control did not worsenadults with type 2 diabetes, in a study
Tesamorelin for memory in older adults without HIVpossible effect on executive function152 people, 20 weeks: overall effect P = 0.03, no significant difference in memorypeople aged 55–87, in a study
Tesamorelin for cognitive impairment with HIVeffect on memory and attention was studied73 people, 1 study, 6 months: no significant difference between groups shown (P = 0.673)adults with HIV, in a study

How it works

The hypothalamus produces growth hormone-releasing hormone (GHRH), and in response the pituitary releases growth hormone in pulses, mostly at night. Tesamorelin repeats the whole 44-amino-acid sequence of human GHRH and carries a small hexenoyl group at the end of the chain that protects the molecule from rapid breakdown. It acts on pituitary cells, they release their own growth hormone, and the level of insulin-like growth factor 1 (IGF-1) rises. According to the label, other pituitary hormones, including TSH, LH, ACTH and prolactin, did not change in a clinically significant way. The half-life of the drug itself is about 11 minutes, so its action goes through the pituitary. The study authors believe the approach preserves the pulsatile rhythm of release and the feedback loop: rising IGF-1 continues to restrain the pituitary. This is the researchers' reasoning; the registration trials did not directly compare it with injections of growth hormone itself.

Visceral fat in HIV lipodystrophy

Lipodystrophy in HIV is a redistribution of fat: more of it collects in the abdomen, around the organs. Visceral adipose tissue (VAT) is measured on computed tomography at the L4–L5 level in square centimeters. The drug was registered on the basis of two double-blind phase 3 studies with an identical design: tesamorelin 2 mg a day under the skin vs placebo, 26 weeks, 2:1 ratio. The first had 412 people (86% men), VAT −15.2% vs +5.0% (Falutz J N Engl J Med 2007. PMID 18057338). The second enrolled 404 people, VAT −10.9% (−21 cm²) vs −0.6% (Falutz J J Acquir Immune Defic Syndr 2010. PMID 20101189).

The pooled analysis of both studies (806 people: 543 on tesamorelin, 263 on placebo) gives VAT −24 vs +2 cm², treatment effect −15.4% (P < 0.001). Triglycerides fell by 0.42 mmol/L (37 mg/dL) vs a rise of 0.07 mmol/L (6 mg/dL) on placebo, and the ratio of total cholesterol to HDL improved. IGF-1 rose by 14.1 nmol/L (108 ng/mL) vs a fall of 0.9 nmol/L (7 ng/mL) (Falutz J J Clin Endocrinol Metab 2010. PMID 20554713).

A meta-analysis of 5 studies: VAT fell by 27.7 cm² (Badran Obes Res Clin Pract 2026. PMID 41545261). A second meta-analysis, this one reporting its sample — 909 people, 4 studies — gave the same figures plus waist −1.6 cm and lean mass +1.4 kg (Ditta J Int Assoc Provid AIDS Care 2026. PMID 42538058); both rely mostly on the same registration studies.

What goes down and what does not

Visceral fat goes down, and with it a little trunk fat. Subcutaneous abdominal fat in the pooled analysis changed non-significantly (−2 vs +2 cm², P = 0.08), and limb fat in the second phase 3 study and body mass index in the meta-analysis were also without significant change (PMID 20554713; PMID 20101189; PMID 41545261). According to the label tables, weight over 26 weeks was −0.4 kg vs 0.0 and +0.5 vs +0.3 kg, differences not significant, while lean mass rose by 1.3 and 1.2 kg with trunk fat −1.0 and −0.8 kg. That is why the label states plainly that the drug is not indicated for weight loss, since it is weight-neutral. It changes body composition, not the number on the scale.

The response differs from person to person; a "responder" is defined as a VAT reduction of at least 8%. The chance of reaching VAT below 140 cm² within 6 months was 3.9 times higher on tesamorelin than on placebo (95% CI 2.03–7.44; 806 people, 2 studies; Mangili A PLoS One 2015. PMID 26457580).

What happens after stopping

The effect lasts while treatment continues. Among 246 people who continued treatment, VAT fell by 17.5% over 52 weeks (2 studies; Falutz J J Clin Endocrinol Metab 2010. PMID 20554713). After switching to placebo, VAT returned by 22% in the first study and by 16% in the second over 26 weeks (FDA label, Table 4), and IGF-1 returns to baseline within 10 weeks of stopping (Baker LD Arch Neurol 2012. PMID 22869065).

Liver fat

Visceral fat is linked to fatty liver disease (formerly NAFLD, now MASLD), and tesamorelin was tested here. In a double-blind study of 61 people with a liver fat fraction of at least 5% (by magnetic resonance spectroscopy), 2 mg a day or placebo was given for 12 months. The liver fat fraction fell by 4.1 percentage points vs placebo (95% CI −7.6 to −0.7; P = 0.018), which is −37% of baseline. It dropped below 5% in 35% on tesamorelin and in 4% on placebo (Stanley TL Lancet HIV 2019. PMID 31611038).

Progression of fibrosis (scar tissue) on paired liver biopsies occurred in 2 people out of 19 (10.5%) on tesamorelin and in 9 out of 24 (37.5%) on placebo, P = 0.04. Existing fibrosis did not decrease: improvement in 2 vs 3 people (P = 0.71). This result is secondary and the number of people is small. An earlier study of 50 people with HIV and abdominal obesity over 6 months showed a fall in liver fat of 2.9 percentage points vs placebo (P = 0.003) alongside VAT −34 vs +8 cm² (Stanley TL JAMA 2014. PMID 25038357). Use in liver disease is not covered by the FDA label.

People without HIV

There are studies in people without HIV too. In a double-blind study of 60 people with abdominal obesity and reduced growth hormone secretion (selected by the GHRH-arginine test), VAT fell by 35 cm² relative to placebo over 12 months (95% CI −58 to −12; P = 0.003). Triglycerides fell by 0.42 mmol/L (37 mg/dL), carotid wall thickness by 0.04 mm, IGF-1 rose by 12.1 nmol/L (92 µg/L), while subcutaneous fat and glucose showed no significant change (Makimura H J Clin Endocrinol Metab 2012. PMID 23015655). In people with type 2 diabetes (53 people, 12 weeks, doses of 1 and 2 mg) fasting glucose, HbA1c and diabetes control did not differ from placebo; the study was commissioned by the manufacturer (Clemmons DR PLoS One 2017. PMID 28617838).

Memory and attention

In a double-blind study of 152 people aged 55–87, 66 of them with mild cognitive impairment, the drug was given at 1 mg at bedtime for 20 weeks. The overall cognitive score improved (P = 0.03), most of all executive function (P = 0.005); verbal memory differed non-significantly (P = 0.08). IGF-1 rose by 117%, and body fat percentage fell by 7.4% with weight unchanged (Baker LD Arch Neurol 2012. PMID 22869065). Adverse events, mostly mild, occurred in 68% vs 36% on placebo. In people with HIV and cognitive impairment, in an open-label study of 73 participants over 6 months, the difference between groups in cognitive function was not significant (P = 0.673), although waist fell by 2.7 cm (Ellis RJ J Infect Dis 2025. PMID 39813152).

IGF-1, blood sugar and safety

A rise in IGF-1 is a direct consequence of the drug's action. According to the FDA label, over 26 weeks IGF-1 exceeded 2 standard deviations (SDS) above the age norm in 47% and 3 SDS in 36%. With persistent values above 3 SDS, consideration of discontinuation is suggested. The label calls the consequences of long-term elevated IGF-1 unknown, and long-term cardiovascular safety has not been established.

Glucose needs attention. On average blood sugar changed non-significantly in the registration trials, but HbA1c 6.5% and above at week 26 was seen in 5% vs 1% on placebo; the hazard ratio for diabetes was 3.3 (95% CI 1.4–9.6). In the liver fat study of 50 people, fasting glucose at 2 weeks rose by 0.50 mmol/L (9 mg/dL) vs 0.11 mmol/L (2 mg/dL), and insulin sensitivity fell by month 3, while by month 6 the difference from placebo was not significant (PMID 25038357). That is why glucose is checked before and during treatment.

Common adverse events over 26 weeks, according to the label, on tesamorelin and on placebo: injection-site reactions 17% and 6%, joint pain 13% and 11%, peripheral edema 6% and 2%. Fluid retention (edema, carpal tunnel syndrome) resolves on its own or after stopping. Hypersensitivity was noted in 4%. Antibodies to the drug were present in 50% by week 26 and did not affect the effect or IGF-1.

How it is used

Indication per the label: reduction of excess abdominal fat in adults with HIV and lipodystrophy. The drug is injected under the skin of the abdomen once a day, rotating injection sites and avoiding scars, bruises and the navel. There are two forms with different doses, and they are not interchangeable. Egrifta WR (11.6 mg vial) is given at 1.28 mg a day; the contents of the vial are mixed with bacteriostatic water, and the solution lasts 7 days. Egrifta SV (2 mg vial) is given at 1.4 mg a day, one dose per vial. The original form at 2 mg a day was used in the registration studies and in the liver fat studies; the newer forms are justified by comparable bioavailability. There is no fixed duration; the label advises reviewing continuation if VAT has not decreased. The drug is not indicated for children, and the label gives no data for people over 65.

Who should see a doctor first

According to the label, the drug is contraindicated in disruption of the hypothalamic-pituitary axis (pituitary removal, hypopituitarism, pituitary tumor or surgery, head irradiation, head trauma), in active malignancy, in hypersensitivity to tesamorelin or its excipients, and in pregnancy. Breastfeeding also rules out its use. With a history of cancer, the decision is made after weighing benefit and risk, since growth hormone is classed among growth factors. In diabetes, eye-fundus monitoring is needed. In critical illness after surgery and trauma, the label suggests considering discontinuation.

What the studies showed

What was studiedWho and how manyResultSource
Visceral fat, pooled analysis806 people, 2 studies, 26 weeks−24 vs +2 cm², treatment effect −15.4%; IGF-1 +14.1 nmol/L (108 ng/mL); weight did not changeFalutz J J Clin Endocrinol Metab 2010. PMID 20554713
Visceral fat, first phase 3 study412 people, 1 study−15.2% vs +5.0%Falutz J N Engl J Med 2007. PMID 18057338
Visceral fat, second phase 3 study404 people, 1 study−10.9% vs −0.6%; subcutaneous fat unchangedFalutz J J Acquir Immune Defic Syndr 2010. PMID 20101189
Extension to 52 weeks and withdrawal246 people continued treatment, 135 switched to placebo, 2 studies−17.5% on treatment; after switching to placebo VAT returnsFalutz J J Clin Endocrinol Metab 2010. PMID 20554713; Falutz J AIDS 2008. PMID 18690162
Dose finding61 people, 1 study, 12 weekstrunk fat −9.2% on 2 mg; VAT with no significant difference from placeboFalutz J AIDS 2005. PMID 16052083
Meta-analysis, HIV lipodystrophy5 studiesVAT −27.7 cm²; BMI and subcutaneous fat unchangedBadran Obes Res Clin Pract 2026. PMID 41545261
Meta-analysis, effect and dropout909 people, 4 studiesVAT decreases, waist −1.6 cm, lean mass +1.4 kg; dropout more frequent on the drug, borderline significance (RR 2.25; 95% CI 0.98–5.17)Ditta J Int Assoc Provid AIDS Care 2026. PMID 42538058
Liver fat, biopsy61 people, 1 study, 12 months−4.1 percentage points (−37%); fibrosis progressed in 2 of 19 vs 9 of 24 (paired biopsies)Stanley TL Lancet HIV 2019. PMID 31611038
Liver fat, first study50 people, 1 study, 6 months−2.9 percentage points; fasting glucose +0.39 mmol/L (+7 mg/dL) at 2 weeksStanley TL JAMA 2014. PMID 25038357
Liver enzymessubgroup with ALT or AST above 30 U/L, 2 studiesin responders ALT −8.9 vs +1.4 U/L in non-respondersFourman LT AIDS 2017. PMID 28832410
Obesity with reduced growth hormone, without HIV60 people, 1 study, 12 monthsVAT −35 cm² vs placebo; triglycerides −0.42 mmol/L (−37 mg/dL)Makimura H J Clin Endocrinol Metab 2012. PMID 23015655
Type 2 diabetes53 people, 1 study, 12 weeksdiabetes control did not worsenClemmons DR PLoS One 2017. PMID 28617838
Memory in older adults without HIV152 people, 1 study, 20 weeksexecutive function P = 0.005; verbal memory P = 0.08Baker LD Arch Neurol 2012. PMID 22869065
Cognitive impairment in HIV73 people, 1 open-label studydifference between groups P = 0.673Ellis RJ J Infect Dis 2025. PMID 39813152
Safety and regimenmanufacturer's labelIGF-1 above 3 SDS in 36%; HbA1c 6.5% and above in 5% vs 1%FDA label EGRIFTA WR, rev. 03/2025

Summary

Tesamorelin is a drug with a precise target: to reduce visceral fat in adults with HIV and lipodystrophy without changing weight or subcutaneous fat. Liver fat is of additional interest, where the first results come with biopsy data, while studies without HIV are still few and concern people with reduced growth hormone. The effect lasts during treatment, so the decision on duration is made together with a doctor, monitoring IGF-1 and glucose. You can discuss whether such a drug fits your situation at a consultation.

Source: Tesamorelin: visceral fat, the liver and what the studies showed — universum.earth. Dr. Pereligyn.

Come back
Request a call back